Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising

Executive Summary

Highlights from the past year's financings include BeiGene's $800m follow-on offering in the US and $903m Hong Kong IPO, Moderna's $560m Series G round and $604m IPO, and Allogene's $300m Series A and $373m IPO.

Advertisement

Related Content

Few Signs Of An IPO Slowdown Despite US Biotech Stock Slump
Strong Innovent IPO Restoring Faith In HK Biotech Listings?
Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'
Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter
Finance Watch: 2018 Biopharma VC Investment Could Beat 2017 One Quarter Ahead Of Schedule
Samumed CMO Hopes To Reach Drug Approvals Via The Wnt Pathway
Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
Celgene Eyes IO Growth With BeiGene China Pact
Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel